In addition, Pasithea has completed initial dosing of three patients in Cohort 4A (15mg capsule). Patient recruitment for Cohort 4B is ongoing (4mg tablet). The Company plans to present interim safety ...

The Safety Review Committee monitoring the clinical trial unanimously approved opening of the third cohort based on its favorable review of Cohort 1 and 2 safety and pharmacokinetic data. Additional ...

OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of allergic reactions (incl. anaphylaxis) and is based on the proprietary AmorphOX® technology.The clinical study, ...

Many of these drugs have shown promise in earlier studies for inhibiting viral replication or exhibit pharmacokinetic properties favorable for therapeutic application. By analyzing this set, we aimed ...

Hyderabad: Suven Life Sciences, a clinical stage biopharmaceutical company discovering and developing novel medicines to ...

PALO ALTO, CA and NEEDHAM, MA, USA and MELBOURNE, Australia I January 08, 2025 I Bitterroot Bio, a leader in developing innovative medicines in the field of ...

RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared delivery ...

Suven Life Sciences surged 9.51% to Rs 138.70 after the firm dosed first subjects in a Phase-1 clinical trial of SUVN-I6107 being conducted in USA under FDA acceptance of investigational new drug (IND ...

Advancement in Nanoparticle-Based NIRF Probes for Precision Visualization in Oncology. Open Access Library Journal, 12, 1-14. doi: 10.4236/oalib.1112471 . Molecular imaging has introduced new ...

A compound derived from Nectandra leucantha, a tree native to southern Brazil (local names: canela-seca or canela-branca), ...

In the MAD cohort, MBX 1416 appeared to increase GLP-1 within 60 minutes of a mixed meal tolerance test, suggesting a ...

The rationale was that commercial mydriatics administered during retinopathy of prematurity (ROP) screening have been ...